Shari Brazinsky
Pulmonary Disease · San Diego, CANPI 1245339340
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $68,823 of the $82,214 with a category attached, or 83.7%. GSK accounts for 90.3% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2022 at $35,893 and has fallen 77.6% since, to $8,053 in 2023. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 418 payments — averaging $196.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$74K
- AstraZeneca$2K
- Boehringer Ingelheim$967
- Regeneron Healthcare Solutions, Inc.$783
- Amgen$653
- Actelion Pharmaceuticals US, Inc.$444
- plus $3K from 34 others
Across 161 payments — averaging $2731.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$180K
- AstraZeneca$81K
- Insmed, Inc.$52K
- Chiesi USA, Inc.$45K
- Roche Products Limited$35K
- Sanofi US Services Inc.$18K
- plus $29K from 3 others
What the payments were for
- Consulting fees$6451%
- Speaking & faculty fees$68,82384%
- Travel & lodging$4,5195%
- Food & beverage$8,02810%
- Education$1710%
- Gifts$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 101 | $74,217 |
| AstraZeneca | 50 | $2,216 |
| Boehringer Ingelheim | 49 | $967 |
| Regeneron Healthcare Solutions, Inc. | 28 | $783 |
| Amgen | 5 | $653 |
| Actelion Pharmaceuticals US, Inc. | 30 | $444 |
| Sanofi | 19 | $378 |
| Merck | 14 | $318 |
| Pfizer | 13 | $232 |
| Insmed, Inc. | 11 | $229 |
| Philips North America LLC | 21 | $204 |
| Mylan Specialty L.p. | 9 | $203 |
| Paratek Pharmaceuticals, Inc. | 7 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $130 |
| Genentech USA, Inc. | 5 | $116 |
| Gilead | 5 | $113 |
| United Therapeutics Corporation | 1 | $100 |
| Grifols USA, LLC | 4 | $90 |
| Sanofi Pasteur Inc. | 6 | $89 |
| Harmony Biosciences LLC | 2 | $60 |
| Johnson & Johnson | 3 | $51 |
| Advanced Respiratory, Inc | 2 | $50 |
| Electromed, Inc. | 3 | $45 |
| Hospira, Inc. | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Resmed Corp | 2 | $36 |
| Medline Industries LP | 2 | $28 |
| Shionogi Inc | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Circassia Inc. | 2 | $26 |
| Melinta Therapeutics, LLC | 1 | $21 |
| Pulmonx Corporation | 2 | $19 |
| Vyera Pharmaceuticals, LLC | 1 | $19 |
| Inogen, Inc. | 1 | $19 |
| Pentax Of America, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Bayer | 1 | $13 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$52,223
- ANORO ELLIPTA$2,400
- BEVESPI AEROSPHERE$1,289
- ZERBAXA$114
- DUPIXENT$114
How this compares
$82,214 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in San Diego
- George ChengSan Diego$291K
- Samir MakaniSan Diego$179K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.